Form 8-K - Current report:
SEC Accession No. 0001213900-21-044571
Filing Date
2021-08-24
Accepted
2021-08-24 15:55:22
Documents
13
Period of Report
2021-08-24
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea146379-8k_immucell.htm   iXBRL 8-K 25541
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED AUGUST 24, 2021 ea146379ex99-1_immucell.htm EX-99.1 17020
  Complete submission text file 0001213900-21-044571.txt   212749

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20210824.xsd EX-101.SCH 3024
4 XBRL LABEL FILE iccc-20210824_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE iccc-20210824_pre.xml EX-101.PRE 22358
6 EXTRACTED XBRL INSTANCE DOCUMENT ea146379-8k_immucell_htm.xml XML 3161
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 211202088
SIC: 2835 In Vitro & In Vivo Diagnostic Substances